LMR Partners LLP Reduces Stock Position in TScan Therapeutics, Inc. (NASDAQ:TCRX)

LMR Partners LLP lowered its stake in shares of TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) by 89.2% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 71,800 shares of the company's stock after selling 593,729 shares during the period. LMR Partners LLP owned about 0.14% of TScan Therapeutics worth $358,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in TCRX. abrdn plc grew its holdings in shares of TScan Therapeutics by 27.2% in the 3rd quarter. abrdn plc now owns 371,655 shares of the company's stock worth $1,851,000 after purchasing an additional 79,511 shares during the last quarter. SG Americas Securities LLC acquired a new stake in TScan Therapeutics during the 3rd quarter worth approximately $78,000. The Manufacturers Life Insurance Company bought a new stake in TScan Therapeutics during the second quarter worth about $90,000. Troluce Capital Advisors LLC acquired a new position in TScan Therapeutics during the 2nd quarter worth approximately $543,000. Finally, Great Point Partners LLC bought a new position in shares of TScan Therapeutics during the second quarter valued at $5,504,000. Institutional investors and hedge funds own 82.83% of the company's stock.

Insider Transactions at TScan Therapeutics

In related news, Director Barbara Klencke bought 5,000 shares of the stock in a transaction dated Friday, August 23rd. The shares were acquired at an average cost of $5.69 per share, for a total transaction of $28,450.00. Following the acquisition, the director now directly owns 35,000 shares in the company, valued at approximately $199,150. This trade represents a 16.67 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Zoran Zdraveski sold 164,686 shares of the firm's stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $5.78, for a total transaction of $951,885.08. Following the sale, the insider now owns 4,716 shares of the company's stock, valued at $27,258.48. This represents a 97.22 % decrease in their position. The disclosure for this sale can be found here. Insiders have purchased 15,947 shares of company stock worth $86,660 over the last quarter. 2.76% of the stock is currently owned by insiders.

TScan Therapeutics Trading Down 4.4 %

TCRX traded down $0.18 on Thursday, hitting $3.94. The company had a trading volume of 235,480 shares, compared to its average volume of 245,976. The business's fifty day simple moving average is $5.17 and its 200 day simple moving average is $6.37. The company has a market cap of $208.70 million, a PE ratio of -3.72 and a beta of 0.79. The company has a quick ratio of 9.56, a current ratio of 9.56 and a debt-to-equity ratio of 0.13. TScan Therapeutics, Inc. has a 12-month low of $3.73 and a 12-month high of $9.69.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.03. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. The company had revenue of $1.05 million for the quarter, compared to analyst estimates of $2.86 million. Equities research analysts expect that TScan Therapeutics, Inc. will post -1.12 EPS for the current year.

Analyst Upgrades and Downgrades

TCRX has been the subject of a number of research reports. Wedbush reissued an "outperform" rating and issued a $10.00 price objective on shares of TScan Therapeutics in a research note on Tuesday, November 5th. HC Wainwright reaffirmed a "buy" rating and set a $15.00 price target on shares of TScan Therapeutics in a research note on Friday, November 15th. Finally, Needham & Company LLC restated a "buy" rating and issued a $11.00 price objective on shares of TScan Therapeutics in a research report on Tuesday, November 12th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $12.00.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.